Breast Cancer | Clinical

RaDaR MRD Test Shows Promise in HR+, HER2- Breast Cancer

June 22, 2022

Updated data from the CHiRP study demonstrates clinical potential with the RaDaR minimal residual disease test in patients with high-risk hormone receptor–positive human epidermal growth factor receptor 2-negative breast cancer.